Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M9466 + irinotecan
- Development stage
- Discontinued
- Lead developer
- Merck KGaA
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
M9466 + irinotecan is an investigational combination therapy being evaluated in advanced solid tumors and colorectal cancer. M9466 is an oral PARP1 inhibitor (poly[ADP-ribose] polymerase 1 inhibitor) designed to inhibit DNA repair in tumor cells, thereby enhancing the cytotoxic effect of chemotherapeutic agents. Irinotecan is a topoisomerase 1 inhibitor that interferes with DNA replication and transcription by causing DNA strand breaks. The combination is studied to exploit potential synergy through dual impairment of DNA repair pathways, potentially improving anti-tumor activity in patients for whom standard therapies have failed.
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on M9466 + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M9466 + irinotecan.